Forty four adult female patients with rheumatoid arthritis (RA), diagnosed in accordance with criteria suggested by 2010 American College of Rheumatology (ACR) criterion, with remission to moderate disease activity score will be recruited in the study. Although patients receiving inconstant drug prescription for 3 weeks before and during the intervention, subjects suffering from inflammatory or metabolic disorders and those with pregnancy or lactation will be excluded. The participants will be assigned into treatment group (22subject) and control group (22subject) using permuted-blocks randomization and will receive two glasses of chamomile and placebo herbal tea for 6 weeks. To determine the effects of chamomile on patient’s clinical status, disease activity score (DAS-28) will be calculated before and after the intervention for each group. Inflammatory biomarkers such as interlukin-1β, TNF-α (tumor necrosis factor-α) and MMP-3 (matrix metalloproteinase 3) will be measured with ELISA method in serum samples collected before and after the study (6weeks). Finally, to manage effects of any confounder variable, anthropometric indicators, physical activity level and mental anxiety status will be measured and a three-day food record will be kept in two period, in onset and end of study.